BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hofman J, Sorf A, Vagiannis D, Sucha S, Kammerer S, Küpper J, Chen S, Guo L, Ceckova M, Staud F. Brivanib Exhibits Potential for Pharmacokinetic Drug–Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Mol Pharmaceutics 2019;16:4436-50. [DOI: 10.1021/acs.molpharmaceut.9b00361] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Tian X, Xiang B, Yu Y, Li Q, Zhang Z, Zhanghuang C, Jin L, Wang J, Mi T, Chen M, Liu F, Wei G. A novel cuproptosis-related subtypes and gene signature associates with immunophenotype and predicts prognosis accurately in neuroblastoma. Front Immunol 2022;13:999849. [DOI: 10.3389/fimmu.2022.999849] [Reference Citation Analysis]
2 Ren Z, Chen S, Qin X, Li F, Guo L. Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline. Arch Toxicol. [DOI: 10.1007/s00204-022-03369-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Liu Y, Li Y, Wang Y, Lin C, Zhang D, Chen J, Ouyang L, Wu F, Zhang J, Chen L. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol 2022;15:89. [PMID: 35799213 DOI: 10.1186/s13045-022-01310-7] [Reference Citation Analysis]
4 Zhang L, Wang X, Wang L, Badawy S, Liu Z, Xie C, Wang X, Tao Y. A new drug-drug interaction-tilmicosin reduces the metabolism of enrofloxacin through CYP3A4. Research in Veterinary Science 2022. [DOI: 10.1016/j.rvsc.2022.05.004] [Reference Citation Analysis]
5 Vagiannis D, Zhang Y, Budagaga Y, Novotna E, Skarka A, Kammerer S, Küpper JH, Hofman J. Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol 2022;434:115823. [PMID: 34896433 DOI: 10.1016/j.taap.2021.115823] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sorf A, Vagiannis D, Ahmed F, Hofman J, Ceckova M. Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol 2021;434:115797. [PMID: 34780725 DOI: 10.1016/j.taap.2021.115797] [Reference Citation Analysis]
7 Vagiannis D, Budagaga Y, Morell A, Zhang Y, Novotná E, Skarka A, Kammerer S, Küpper JH, Hanke I, Rozkoš T, Hofman J. Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. Int J Mol Sci 2021;22:11936. [PMID: 34769363 DOI: 10.3390/ijms222111936] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Chen S, Wu Q, Li X, Li D, Mei N, Ning B, Puig M, Ren Z, Tolleson WH, Guo L. Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity. J Environ Sci Health C Toxicol Carcinog 2021;39:68-86. [PMID: 33576714 DOI: 10.1080/26896583.2021.1880242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Namasivayam V, Silbermann K, Pahnke J, Wiese M, Stefan SM. Scaffold fragmentation and substructure hopping reveal potential, robustness, and limits of computer-aided pattern analysis (C@PA). Comput Struct Biotechnol J 2021;19:3269-83. [PMID: 34141145 DOI: 10.1016/j.csbj.2021.05.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Hofman J, Vagiannis D, Chen S, Guo L. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact 2021;340:109448. [PMID: 33775687 DOI: 10.1016/j.cbi.2021.109448] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
11 Zhao Y, Chen Y, Wang J, Liu L. Effects of ATP-binding cassette transporter G2 in extracellular vesicles on drug resistance of laryngeal cancer cells in in vivo and in vitro. Oncol Lett 2021;21:364. [PMID: 33747221 DOI: 10.3892/ol.2021.12625] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Zou D, Li Z, Lv F, Yang Y, Yang C, Song J, Chen Y, Jin Z, Zhou J, Jiang Y, Ma Y, Jing Z, Tang Y, Zhang Y. Pan-Cancer Analysis of NOS3 Identifies Its Expression and Clinical Relevance in Gastric Cancer. Front Oncol 2021;11:592761. [PMID: 33747912 DOI: 10.3389/fonc.2021.592761] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
13 Liang Q, Wang J, Zhao L, Hou J, Hu Y, Shi J. Recent advances of dual FGFR inhibitors as a novel therapy for cancer. Eur J Med Chem 2021;214:113205. [PMID: 33556787 DOI: 10.1016/j.ejmech.2021.113205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
14 Cavanah P, Itou J, Rusman Y, Tahara N, Williams JM, Salomon CE, Kawakami Y. A nontoxic fungal natural product modulates fin regeneration in zebrafish larvae upstream of FGF-WNT developmental signaling. Dev Dyn 2021;250:160-74. [PMID: 32857425 DOI: 10.1002/dvdy.244] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Vagiannis D, Yu Z, Novotna E, Morell A, Hofman J. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochemical Pharmacology 2020;178:114061. [DOI: 10.1016/j.bcp.2020.114061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Vagiannis D, Novotna E, Skarka A, Kammerer S, Küpper JH, Chen S, Guo L, Staud F, Hofman J. Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers (Basel) 2020;12:E813. [PMID: 32231067 DOI: 10.3390/cancers12040813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]